Oncology Corporate Profile
Constellation Pharmaceuticals leverages insights from the rapidly expanding field of epigenetics to discover and develop small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The company’s innovative product discovery engine targets both enzymes that modify the dynamic structure of chromatin (writers and erasers) and other proteins that interact with chromatin (readers) to control gene expression. Restoration of normal gene expression through chromatin modulation by highly selective and specific inhibitors promises to be a powerful approach to the development of important new medicines against a broad range of diseases.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|CPI-0610||BET protein bromodomain inhibitor||Multiple Myeloma||I|
|CPI-0610||BET protein bromodomain inhibitor||Myelodysplastic Syndrome (MDS)||I|
|CPI-1205||EZH2 inhibitor||Non-Hodgkin's Lymphoma (NHL)||I|
|CPI-0610||BET protein bromodomain inhibitor||Non-Hodgkin's Lymphoma (NHL)||I|
View additional information on product candidates here »